Credit Suisse’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-11,657
| Closed | -$123K | – | 3223 |
|
|
2023
Q1 | $123K | Buy |
11,657
+2
| +0% | +$61 | ﹤0.01% | 3187 |
|
|
2022
Q4 | $395K | Buy |
11,655
+134
| +1% | +$6.49K | ﹤0.01% | 2915 |
|
|
2022
Q3 | $553K | Sell |
11,521
-319
| -3% | -$19K | ﹤0.01% | 2728 |
|
|
2022
Q2 | $674K | Sell |
11,840
-1,928
| -14% | -$122K | ﹤0.01% | 2650 |
|
|
2022
Q1 | $1.11M | Buy |
13,768
+3,001
| +28% | +$444K | ﹤0.01% | 2479 |
|
|
2021
Q4 | $2.18M | Sell |
10,767
-1,658
| -13% | -$360K | ﹤0.01% | 2722 |
|
|
2021
Q3 | $3.35M | Buy |
12,425
+834
| +7% | +$201K | ﹤0.01% | 2387 |
|
|
2021
Q2 | $2.98M | Sell |
11,591
-2,411
| -17% | -$667K | ﹤0.01% | 2524 |
|
|
2021
Q1 | $4.2M | Sell |
14,002
-2,064
| -13% | -$642K | ﹤0.01% | 2221 |
|
|
2020
Q4 | $4.1M | Sell |
16,066
-38,557
| -71% | -$9.96M | ﹤0.01% | 2265 |
|
|
2020
Q3 | $13.6M | Sell |
54,623
-10,316
| -16% | -$3.24M | 0.01% | 1208 |
|
|
2020
Q2 | $22.6M | Sell |
64,939
-15,409
| -19% | -$4.81M | 0.02% | 889 |
|
|
2020
Q1 | $21.5M | Buy |
80,348
+35,472
| +79% | +$11M | 0.02% | 805 |
|
|
2019
Q4 | $14.5M | Sell |
44,876
-8,185
| -15% | -$2.37M | 0.01% | 1209 |
|
|
2019
Q3 | $14.5M | Buy |
53,061
+15,043
| +40% | +$5.52M | 0.01% | 1106 |
|
|
2019
Q2 | $20.3M | Buy |
38,018
+6,414
| +20% | +$3.22M | 0.02% | 924 |
|
|
2019
Q1 | $15.9M | Sell |
31,604
-33
| -0.1% | -$19.6K | 0.01% | 984 |
|
|
2018
Q4 | $15.6M | Sell |
31,637
-1,215
| -4% | -$733K | 0.02% | 923 |
|
|
2018
Q3 | $30M | Buy |
32,852
+2,266
| +7% | +$1.93M | 0.03% | 653 |
|
|
2018
Q2 | $22.4M | Buy |
30,586
+4,454
| +17% | +$5.14M | 0.02% | 779 |
|
|
2018
Q1 | $41.7M | Buy |
26,132
+3,613
| +16% | +$4.65M | 0.04% | 485 |
|
|
2017
Q4 | $20.2M | Sell |
22,519
-1,915
| -8% | -$1.13M | 0.02% | 876 |
|
|
2017
Q3 | $8.8M | Buy |
24,434
+4,824
| +25% | +$1.51M | 0.01% | 1328 |
|
|
2017
Q2 | $5.75M | Sell |
19,610
-3,454
| -15% | -$998K | 0.01% | 1546 |
|
|
2017
Q1 | $8.12M | Sell |
23,064
-12,324
| -35% | -$2.77M | 0.01% | 1327 |
|
|
2016
Q4 | $6.51M | Buy |
35,388
+2,069
| +6% | +$421K | 0.01% | 1473 |
|
|
2016
Q3 | $8.59M | Buy |
33,319
+976
| +3% | +$251K | 0.01% | 1301 |
|
|
2016
Q2 | $6.9M | Buy |
32,343
+6,204
| +24% | +$1.39M | 0.01% | 1415 |
|
|
2016
Q1 | $5.39M | Sell |
26,139
-1,071
| -4% | -$206K | 0.01% | 1470 |
|
|
2015
Q4 | $6.88M | Sell |
27,210
-532
| -2% | -$109K | 0.01% | 1371 |
|
|
2015
Q3 | $4.56M | Sell |
27,742
-16,363
| -37% | -$2.89M | 0.01% | 1628 |
|
|
2015
Q2 | $8.28M | Buy |
44,105
+13,672
| +45% | +$2.35M | 0.01% | 1381 |
|
|
2015
Q1 | $5.02M | Sell |
30,433
-3,695
| -11% | -$759K | 0.01% | 1665 |
|
|
2014
Q4 | $7.93M | Buy |
34,128
+8,613
| +34% | +$1.84M | 0.01% | 1430 |
|
|
2014
Q3 | $4.62M | Buy |
25,515
+5,794
| +29% | +$1.11M | ﹤0.01% | 1813 |
|
|
2014
Q2 | $3.79M | Buy |
19,721
+1,931
| +11% | +$342K | ﹤0.01% | 2197 |
|
|
2014
Q1 | $3.23M | Sell |
17,790
-452
| -2% | -$89.5K | ﹤0.01% | 2128 |
|
|
2013
Q4 | $3.1M | Buy |
18,242
+5,402
| +42% | +$871K | ﹤0.01% | 2259 |
|
|
2013
Q3 | $2.01M | Sell |
12,840
-16,413
| -56% | -$3.03M | ﹤0.01% | 2386 |
|
|
2013
Q2 | $5.07M | Buy |
+29,253
| New | +$4.49M | 0.01% | 1555 |
|
Other funds holding NKTR
DTC
MAM
SCM
Credit Suisse's NKTR Position: Q2 2023 in Review
Credit Suisse sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 11,657 shares — an estimated $123K sold.
Credit Suisse first reported a position in NKTR in Q2 2013 and held it in 40 quarters. The position peaked at $41.7M in Q1 2018. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.
- Credit Suisse reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
- Credit Suisse sold 11,657 Nektar Therapeutics shares in Q2 2023, an estimated $123K.
- Credit Suisse first reported a position in Nektar Therapeutics in Q2 2013 and held it in 40 quarters.
- Credit Suisse's Nektar Therapeutics position peaked at $41.7M in Q1 2018.
- 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.
Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.